TheraCryf PLC
8EV
Company Profile
Business description
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Is this the catalyst US tech giant needs?
Muse models may just be the spark that the rirm needed in AI model development.
stocks
ASX share plunges due to Iran related weakness
Despite headwinds our long-term outlook is unchanged.
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,113.40 | 6.40 | 0.07% |
| CAC 40 | 8,189.65 | 69.95 | -0.85% |
| DAX 40 | 23,570.12 | 233.83 | -0.98% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,562.54 | 37.99 | -0.36% |
| HKSE | 25,660.85 | 232.69 | -0.90% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,502.77 | 421.34 | -0.74% |
| NZX 50 Index | 13,020.18 | 161.26 | -1.22% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,926.00 | 14.20 | 0.16% |
| SSE Composite Index | 3,988.56 | 2.33 | 0.06% |